Today's Date
Daratumumab and Belatacept for Desensitization
(
ATTAIN
)
ITN Protocol #:
ITN090ST
Branded Name:
ATTAIN
ClinicalTrials.Gov ID:
NCT04827979Treatment Protocol #:
Therapeutic Area:
Transplantation
Current Status:
Enrollment
Summary:
A Mechanistically Driven Therapy to Desensitize >98.0% cPRA Patients: Depletion of Plasma Cells With Anti-CD38 and Prevention of B Cell Activation With Costimulation Blockade
Clinical Operations Associate Director
Clinical Operations Manager
ITN Biologist
ITN Clinical Trial Physician
NIAID Regulator Officer
Study Personnel:
